The Association of the British Pharmaceutical Industry (ABPI) has suspended the membership of Novo Nordisk for two years due to serious breaches of its Code
of Practice.
The action was taken by the ABPI Board following an investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA)
which found Novo Nordisk to be in breach of the ABPI Code of Practice, including Clause 2 which deals with actions "likely to bring discredit on, or reduce
confidence in, the pharmaceutical industry".
Having considered the case and requesting a further detailed audit of Novo Nordisk's compliance processes, the ABPI Board decided to suspend Novo Nordisk from ABPI
membership.
Susan Rienow, President-Elect, ABPI, said: "The ABPI Board has carefully considered the PMCPA's case report into Novo Nordisk and the subsequent audit of their
compliance procedures.
"The Board expressed significant concern about Novo Nordisk's compliance activities and the very serious issues identified. As a result, the ABPI Board have taken
the decision to suspend Novo Nordisk from ABPI membership.
While thanking the provisionally registered pharmacists and their employers for supporting NHS services during the pandemic, the General Pharmaceutical Council (GPhC) has asked the 63 eligible candidates to join the main register by January 31 to continue practicing.
A total number of 4,799 provisionally-registered pharmacists have been on the provisional register since it was introduced in July 2020 in response to the Covid-19
pandemic, which had affected the registration assessment schedule.
As of Tuesday (January 18), 237 were still on the provisional register, of which 84 have begun the process to join the main register, 90 did not sat an assessment, while 63 eligible candidates are yet to start their application.
The register enabled trainees who had completed their training to support NHS services and provide patient care effectively as provisionally-registered pharmacists,
while they waited to sit the registration assessment.
After providing three potential opportunities to trainees to sit the registration assessment - in March, July and November 2021, the provisional register will close
on January 31, 2022.
The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service.
The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are
needed to fully maximise the benefits of the service.
It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden;
and further developing a tandem model of working comprising hubs with in-practice activity
The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service.
They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians.
Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.
Titan PMR has been accredited by the NHS to provide electronic prescription services (EPS) to dispensing doctors.
Over 1,000 of these doctors, who provide a vital service to almost 10 million people in rural communities, can now offer their patients the same level of benefits
and efficiencies that electronic prescriptions and Titan PMR have brought to pharmacies around the UK.
These features will also increase efficiency for dispensing doctors, who will reduce dispensing errors and improve organisation, increasing their capacity while
enjoying the ability to integrate with other technologies.
After a full year of testing, including six months of compliance testing at a practice in Cumbria, the new accreditation for Titan also has potential to help the
NHS fulfil its target of all prescriptions being issued electronically.
Currently written paper prescriptions from dispensing doctors account for around seven per cent of the total prescriptions in England - around 6.5 million each month.
"Until now dispensing doctor surgeries have basically been in the digital dark ages when it comes to dispensing medicines," said Tariq Muhammad, a tech entrepreneur
and CEO of Bristol-based Invatech Health, which developed Titan PMR.
The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on
vaccination.
It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one.
HSCC said: "The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However,
if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK's position as a global
leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference."
It recommended a more flexible delivery model making use of a wider range of healthcare professionals.
"The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider
array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around
how voices other than NHSE can communicate important messaging around vaccination programmes," it suggested.
Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical
Industry (ABPI).
The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI.
In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice
Authority (PMCPA).
Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI.
All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while
also supporting economic growth for the UK.
Doctors are highly driven professionals seeking exceptional care and service for their clients. Some doctors may have private practices, while others serve
in different capacities in various healthcare institutions. Doctors are among the busiest professionals in the field and may also experience burnout if they're not
careful.
Fortunately, there's an alternative to such a scenario, and more and more healthcare professionals are looking into it. Locum tenens jobs are on the rise as doctors,
and other health workers seek to take advantage of various benefits that can lead to a better career. While doctors hold down their private practice, they also work
with other institutions and colleagues to provide expertise to patients in other locations. This can be rewarding as the doctors can improve their craft tremendously.
Here are some reasons to consider if you wish to explore locum tenens posts.
Better control and schedule flexibility
While career stability is quite important for most doctors, it can be intense for some and lead to burnout. When taking a locum tenens position, a doctor will have
the opportunity to explore other horizons that present themselves. They can see other patients and be exposed to scenarios that may not be present in their practice.
Locum posts also allow you to set your schedule and be flexible with your working hours as necessary. It can lead to better performance and job satisfaction, too.
Opportunity for better income
Accepting a locum position may entail getting extra shifts at another hospital or clinic. It may also mean getting some time with patients during your off days. You
can receive a significant bump to your income as you get to earn more aside from your regular salary. If you're looking to pay off student loans, build a college
fund for your kids, or set up an account to buy a house, working with locum posts may be the key.
Are you interested in a career helping others improve their overall health and wellbeing through nutrition? Becoming a nutritionist is an excellent way to
make a positive impact on the lives of your patients. Nutritionists are experts in understanding how food affects our bodies, so they can provide advice on healthy
eating habits, dietary requirements for certain medical conditions, and more.
However, it takes more than just interest to become a successful nutritionist - there are specific qualifications and experience that you need to have before you
can practice as one. In this blog post, we will look at what it entails so that you can start planning your journey toward becoming a certified professional
nutritionist. We'll cover the education needed for certification, any licensing or registration requirements necessary for practicing in different states or
countries, what kind of skillset potential employers might be looking for when hiring nutritional professionals, and finally some tips on gaining practical
experience while working towards full accreditation. So if you are serious about becoming a nutritionist, let's get started!
FORMAL EDUCATION REQUIREMENTS
The first step towards becoming a certified professional nutritionist is often completing an accredited program in either dietetics or nutrition. A Bachelor's degree
in Nutrition Science, Food Science, and Human Nutrition or Dietetics would be the minimum qualification for entry-level positions as a nutritionist. However, there
are many advanced courses available that can take you further in this field such as Master of Nutrition programs and postgraduate degrees.
Thanks to the NHS primary care access recovery plan, more than 23 million people can now view test results and check their consultation notes online without
needing to contact their GP practice.
NHS England on Monday (4 December) announced that over 81 GP practices in England (more than four in five) are now giving patients access to their new health
records online through the NHS App.
In May, the NHS announced the primary care access recovery plan setting a target of 9 in 10 GP practices offering patients access to their records through the
NHS App by March 2024.
By making access to healthcare easier and quicker, the NHSE also aims to free up to 10 million GP appointments a year by next winter.
The British Medical Association (BMA) has urged non-GP partners and contractors, including pharmacists, nurses, and physiotherapists, to support their
"Protect Your Patients, Protect Your GP Practice" campaign, which was launched to protest changes to the 2024/25 GP contract.
GP contractors and partners across England have strongly opposed the modifications to the GMS contract, leading to an ongoing dispute with the NHS.
The BMA highlights that general practice in England currently receives just 6 pence of every NHS pound and an average GMS 'global sum' of £107.57 per registered
patient annually.
Since 2018/19, CPI erosion to the GMS contract has resulted in a loss of £659 million, or 6.6%. This financial strain has contributed to the closure or merger
of over 1,300 practices over the past decade.
To address these issues, the BMA is urging all GP contractors and partner members to vote YES in the GPC England non-statutory ballot, which will be open
until July 29.
The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry.
The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations.
"I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.
GSK is helping pharmacists to tap into Self Care Week this November, and remind patients how they can adopt a more proactive approach in looking after their health. This includes treating ailments, such as joint pain, over the counter to take pressure off GPs where possible.
Joint pain complaints take up a significant amount of general practice resource with 57 per cent of pain presentations reported relating to joint pain[1], as well as 23 per cent of sufferers feeling as though their pain impacts their quality of life[2].
Many of these complaints and ailments could be addressed with treatment recommendations from a pharmacist with support from Voltarol.
GSK, manufacturer of Voltarol (the market leader in the pain relief topic category[3]), offers support through both its products and resources in hopes to advocate over-the-counter treatments.
The Association of the British Pharmaceutical Industry (ABPI) has announced that Pinder Sahota has decided to step down as President of the ABPI.
ABPI stated that he has made this decision to "avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital
work of the ABPI".
Richard Torbett, Chief Executive, ABPI, said: "Pinder is a passionate advocate for the industry, and I want to thank him for his valuable contribution as ABPI
President.
"I fully respect Pinder's decision to step down as ABPI President which will in no way affect the ongoing case relating to Novo Nordisk. Any breach of the ABPI
Code is taken extremely seriously and it is essential that all regulatory actions are robust, fair and transparent."
ABPI Vice-President, Susan Rienow, Country President of Pfizer, will temporarily take on the roles and responsibilities of the ABPI President until a new President
is chosen by the ABPI Board.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) have issued a joint enforcement notice about
the 'illegal' advertising of Kenalog injections on digital platforms.
The notice warns all organisations offering Kenalog as a 'hay fever treatment' to stop advertising it in any of their social media or website advertising.
"Kenalog is a prescription-only medicine (POM), which must not be directly or indirectly advertised to the public. Kenalog is not licensed for the treatment of hay
fever in the UK, although it is offered by some beauty and aesthetics clinics, under the personal responsibility of an individual prescriber, and advertised widely
on social media," said MHRA.
"Now, advertisers must ensure that all references to Kenalog in the text, images or emojis on social media are removed, as well as commonly-used descriptive phrases
for the jab such as 'hay fever injection' or hay fever jab' or any account names, testimonials or memes by 29 August 2022."
After this date, the CAP's compliance team will remove non-compliant ads using targeted software and those who continue to promote it may be referred to the MHRA for
further enforcement action.
The General Pharmaceutical Council (GPhC) Fitness to Practise Committee decided to remove a pharmacist from the GPhC Register at a 'remote videolink' hearing
held on 13 - 14 April.
"The decision will not take effect until 12 May 2023 or, if an appeal is lodged, once that appeal has been concluded," the committee said.
Kapil Ramesh Rabadia, a pharmacist first registered on 25 July 2011 with GPhC under registration number 2075823 was convicted of 'fraud by abuse of position' and
'being concerned in supplying controlled drugs' following a guilty plea on 13 September 2021.
He was sentenced to 12 months imprisonment for the fraud by abuse of position and six months in respect of supplying a 3 Class B drug. However, the interim suspension
set out in the decision takes effect immediately and will lapse when the removal decision takes effect or once any appeal is concluded.
Between May 2018 and June 2019, Kapil ordered codeine linctus and Phenergan in excess of 100 bottles of each for four men who threatened him with knives and guns.
The men told the pharmacist that he needed to continue to make the supplies or "there would be consequences" for him and his family.
The Pharmacists' Defence Association (PDA) has called for a mandatory training for those who wish to sign fit notes.
The union said it will be seeking urgent clarification around the rollout of guidance and timescales of when this will be available to PDA members working in
primary care and hospitals, who will be at the forefront of the implementation.
"As with any activity, regulated health professionals will be expected to ensure they have received adequate training and guidance before taking on new elements
of practice and to ensure they are acting within the limits of their professional competency," said the association.
It also highlighted that completing a fit note may have an impact on the income received by the patient and therefore the consequences of supplying the document
could mean a direct financial consequence for them, such as eligibility for sick pay or insurance claims, as well as a health outcome.
The PDA expects the mandatory training to cover any factors which will need to be considered in this regard so that pharmacists understand any limitations on when,
how, and for who they might complete the fit notes.
The Pharmacists' Defence Association (PDA) has raised concern over the Health Education England (HEE)'s decision on cutting funding to independent prescribing
training.
The HEE has reportedly decided that no funding will be available to back-fill trainees undertaking the pharmacist independent prescribing (PIP) qualification, or
for the supervision of trainees by DPPs and DMPs.
The PDA noted that, whilst all successful trainee pharmacists will be entering the GPhC register as independent prescribers from 2026, the existing pharmacist
workforce is reliant on opportunities to undertake prescriber training through release from their employment, and the ability to secure a Designated Medical
Practitioner (DMP) or Designated Prescribing Practitioner (DPP) to support the 90 days of supervised practice required.
The association said it has already heard examples of potential DMPs or DPPs requesting a significant fee from trainees before they will provide supervision,
adding that meeting that request is not an option for many.
"This latest decision threatens to undermine the availability of the large numbers of pharmacists seeing supervisors as more IP training becomes available," it
said in a statement.
The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about
the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues.
NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that
salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024.
As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers.
It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.
"Our main concerns are that the use of what they call an asynchronous supply, where the prescriber neither sees nor talks to the patient at the time they
issue the prescription, does lay itself open to perhaps people getting hold of medication that they shouldn't," the Head of Policy, PDA said.
The Pharmacists' Defence Association (PDA) engages in a critical conversation on BBC Radio 4's Woman's Hour, shedding light on the online prescribing of weight
loss drugs and advocating for safer practices.
The PDA's spokesperson, Head of Policy Alima Batchelor, emphasised the importance of adhering to professional guidelines to ensure patient safety and mitigate
regulatory concerns.
During the feature, the PDA highlighted the complexities and risks associated with online supply chains, stressing the necessity for direct clinical consultations
and pharmacist involvement in medication management.
""There are guidelines and advice about verification within the DiCE guidance, but it doesn't go quite far enough for us. We are concerned when patients decline
to allow the online prescriber to advise their GP of what they're taking," Batchelor highlighted.
The Pharmacists' Defence Association (PDA) has made the its 'Education revision programme' accessible for new registrations who are preparing for the GPhC/PSNI
November 2022 assessment.
The programme offers a wide range of practice calculations questions, some mock exams, practical tips on revision, and an opportunity to chat to other PDA members
who are preparing to sit the assessment.
PDA's charity partners, Pharmacist Support also offer a range of options including- Counselling and peer support; Financial support; A listening friend service and
Addiction support.
Candidates can also access the Wardley Wellbeing Service here. This is a resource to help candidates to prioritise their mental, physical and emotional health
through individual and group training.
The PDA has also reminded all candidates that there have been some changes made by the GPhC to address problems that occurred in the June 2022 sitting.